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Key Points
1. De novo malignancy is one of the leading causes of
late mortality after liver transplantation.
2. The risks of skin cancers and lymphoma are more
than 10-fold greater than the risks in an age-matched
and sex-matched general population.
3. Some types of neoplasia, such as lung, head and
neck, and colorectal cancer, are more frequent in liver
transplant recipients than in an age-matched and sex-
matched population. The risks of other frequent ma-
lignancies, such as prostate and breast cancer, do not
seem to be increased.
4. The most important risks for posttransplant malig-
nancy are Epstein-Barr virus seronegativity (for lym-
phoma), sun exposure (for skin cancer), smoking, and
increasing age.
5. Despite the absence of evidence, general recom-
mendations (such as avoidance of overimmunosup-
pression, sunlight protection, and cessation of smok-
ing) should be given. Screening protocols may help to
detect neoplasia at an early stage of disease. Liver
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Liver transplant recipients are at risk of developing de
novo neoplasia through a variety of mechanisms. Im-
munosuppressive therapy decreases immune surveil-
lance against malignant cells and against a variety of
viruses that have oncogenic properties. Moreover, cer-
tain immunosuppressive drugs may have intrinsic on-
cogenic properties. As a result, liver transplant recipi-
ents have an increased risk of de novo neoplasia. For
instance, in a recently published randomized trial, pa-
tients with alcoholic cirrhosis had a higher risk of non-
hepatic neoplasia if they were transplanted than if they
received standard care (5-year risk of neoplasia: 37%
versus 6%).1
Overall, the risk of malignancy is 2 to 4 times higher
in transplant recipients than in an age-matched and
sex-matched population2-6 (Table 1 and Fig. 1). This
increased risk is especially high in neoplasia related to
viral infections,7 such as non-Hodgkin lymphoma, Ka-
posi’s sarcoma, and uterine cervical cancer. The risk of
skin cancer is also greatly increased.3-6,8 The incidence
of other common malignancies also seems to be in-
creased, but this risk is not so high. Some series have
shown that the risk of colorectal,3,5 lung,9 head and
neck,10 urological,3 and hepatocellular carcinomas11
are increased. In some cases, the cause of this in-
creased risk may be a speciﬁc association between cer-
tain causes of liver disease and risk factors for the
development of certain types of neoplasia in the general
population. This is very important in 2 circumstances.
First, there is the association between primary scleros-
ing cholangitis and ulcerative colitis, which markedly
increases the risk of colorectal cancer. Second, patients
with alcoholic liver disease may have an increased risk
of neoplasia because a high intake of alcoholic bever-
ages is associated with a higher risk of esophageal can-
cer and head and neck cancer and also because of the
association between high alcohol intake and smoking,
which is an important risk factor for some of the most
frequently diagnosed tumors in transplant recipients.
In fact, this increased risk has not been adjusted for
well-known risk factors of neoplasia. Finally, the risk of
other common neoplasia types such as prostate and
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breast cancer does not seem to be increased in liver
transplant recipients.9 As a result, the risk of mortality
due to neoplasia is signiﬁcantly higher than that in the
general population,2,3 and de novo neoplasia is one of
the most common causes of mortality after transplan-
tation, mainly in the long term.12 In our experience (Fig.
2), more than 30% of late deaths are caused by de novo
malignancy, and de novo malignancy is the single most
frequent cause of death after liver transplantation.
The outcomes after the diagnosis of malignancy in
liver transplant recipients seem to be worse than the
outcomes in the general population. Unfortunately,
there have been no studies that have conﬁrmed
whether this is true and whether it results from a more
advanced stage at diagnosis, from more aggressive be-
havior of neoplasia in transplant recipients, or from the
presence of comorbidities.
RISK FACTORS OF NEOPLASIA
Immunosuppression
The intensity of immunosuppressive treatment has
been related to the development of neoplasia. For in-
stance, antilymphocyte antiglobulin therapy increases
the risk of lymphoproliferative disorders,13 and aza-
thioprine may be related to the development of cutane-
ous neoplasia.14 In relation to the use of calcineurin
inhibitors, cyclosporine has been related to a greater
risk of cutaneous neoplasia,14 but tacrolimus has been
related to a higher incidence of internal neoplasia.15
The antiproliferative effect of mammalian target of rapa-
mycin (mTOR) inhibitors may be associated with a pro-
tective effect against neoplasia. In fact, several retro-
spective analyses have shown that renal transplant
recipients receiving sirolimus-based immunosuppres-
sive therapy have a lower incidence of cutaneous ma-
lignancies.16
Age
The incidence of neoplasia according to age has a U
shape. In children and young adults, the incidence of
neoplasia is high because of the high incidence of lym-
phoma at these ages. This is because their Epstein-Barr
virus (EBV) status before transplantation is frequently
negative, and EBV-seronegative patients have the high-
est risk of lymphoma.13 In young adults, the risk of
malignancies is lower, and this risk increases with age,
just as in the general population. In fact, the increased
risk of malignancy is one of the most important causes
of lower survival after the transplantation of older re-
TABLE 1. Relative Risks of Neoplasia in Liver
Transplant Recipients in Comparison with a Sex-
Matched and Age-Matched Population
Type of Neoplasia Relative Risk
Overall 2–4
Squamous and basal
cell skin cancer
20–70
Lymphoma 10–30
Head and neck cancer 4–7
In alcoholic liver
disease
25
Lung cancer 1.7–2.5
Colorectal cancer 3–12
In ulcerative colitis 25–30
Prostate cancer Not increased
Breast cancer Not increased
Kidney cancer 5–30
Kaposi’s sarcoma 100
Hepatocellular
carcinoma
3.4
NOTE: The data in this table were taken from Herrero et
al.,2 Haagsma et al.,3 Sheiner et al.,4 Oo et al.,5 Åberg et
al.,6 Fung et al.,9 Herrero et al.,10 and Hoffmann et al.11
Tumors are listed in the order of frequency.
Figure 1. Risk of de novo malignancy after liver transplan-
tation in 322 liver transplant recipients with survival greater
than 3 months after transplantation (April 1990 to January
2009).
Figure 2. Causes of death after liver transplantation at
Clinica Universidad de Navarra (April 1990 to April 2009; 90
deaths/340 transplanted patients).
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cipients.17 Figure 3 shows the risk of de novo malig-
nancy according to age in our series.
Risk Factors Speciﬁc for Different Types of
Neoplasia
Lymphoma
As previously mentioned, the most important risk fac-
tor for lymphoproliferative disease is EBV infection
(more frequently when the recipient is EBV-negative).
Other potential risk factors are the use of OKT3 and
antithymocyte globulins, hepatitis C virus infection,
and cytomegalovirus infection.
Cutaneous Neoplasia
Kaposi’s sarcoma is closely associated with human her-
pesvirus 8 infection. The main risk factors for squa-
mous cell and basal cell carcinomas are skin type and
sun radiation8; other potential risk factors are infection
by human papillomavirus, hepatocellular carcinoma,
primary sclerosing cholangitis, and the immunosup-
pression received,14 but the role of these factors is less
clear.
Upper Aerodigestive Tract and Lung Cancer
As in the general population, smoking is associated
with a higher risk of esophageal, head and neck, and
lung cancer. It is also probably associated with a higher
risk of urological (other than prostate) neoplasia. In
fact, smoking is an independent risk factor for noncu-
taneous malignancy after liver transplantation2 (Fig. 4).
Alcohol seems to also be an important risk factor for the
development of head and neck cancer and esophageal
cancer.18
Colorectal Cancer
Patients with ulcerative colitis associated with primary
sclerosing cholangitis have a high risk of developing
colorectal cancer5 if they have an intact colon. It is not
clear whether this risk is due only to long-term ulcer-
ative colitis or also to immunosuppressive therapy.
PREVENTION AND EARLY DIAGNOSIS
Survival after the diagnosis of de novo malignancy is
low. If skin cancers are excluded, median survival after
neoplasia diagnosis is lower than 3 years (Fig. 5). There-
fore, a program of neoplasia surveillance could have a
positive impact on survival.
Figure 3. Risk of de novo malignancy after liver transplan-
tation in 322 liver transplant recipients with survival greater
than 3 months after transplantation (April 1990 to January
2009) according to their age at transplantation (older or
younger than 60 years; P < 0.001).
Figure 4. Risk of de novo malignancy after liver transplan-
tation in 322 liver transplant recipients with survival greater
than 3 months after transplantation (April 1990 to January
2009) according to smoking status (P < 0.001).
Figure 5. Survival after the diagnosis of de novo malignancy
in 51 liver transplant recipients who were diagnosed with a
noncutaneous malignancy (from a total population of 322 pa-
tients with a follow-up greater than 3 months).
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Some of the neoplasia screening programs in general
populations have insufﬁcient evidence to be recom-
mended.19 Similarly, none of the recommendations for
the prevention and early detection of malignancy after
liver transplantation are based on scientiﬁc evidence.
The ﬁrst recommendation is to avoid overimmuno-
suppression, as it has been suggested that intense reg-
imens of immunosuppression are associated with a
higher frequency of malignancy.15 The use of mTOR
inhibitors could be associated with a lower incidence of
neoplasia, but this beneﬁt has been shown only in ret-
rospective studies in renal transplant patients, and it is
nearly restricted to skin cancer, which infrequently
leads to death.16 Other potential measures are related
to speciﬁc types of neoplasia.
Lymphoproliferative Disease
It has been shown that patients who develop posttrans-
plant lymphoproliferative disease have higher levels of
EBV DNA than those who do not develop it.13 Thus,
monitoring of the EBV DNA load has been suggested to
be of value in the early diagnosis of lymphoma. Unfor-
tunately, there is no clear threshold value predictive for
lymphoproliferative disease. Therefore, it has been pro-
posed that the evolution of the EBV viral load or the
combination of the EBV DNA load and EBV-speciﬁc
cytotoxic T lymphocyte responses may be more useful.
Two approaches have been suggested for patients with
a high risk of posttransplant lymphoproliferative dis-
ease according to the EBVDNA load: antiviral therapy20
and a gradual decrease in immunosuppressive thera-
py.21
Skin Cancer
As skin cancer is the most frequent cancer after trans-
plantation, some authors have suggested that trans-
plant recipients should be evaluated every year by a
dermatology specialist. With this approach, skin cancer
can be diagnosed during early stages, and this would
allow curative resections in all cases8 (in transplant
recipients, skin cancer with an aggressive course and
metastatic spread has been reported). Protection
against sunlight seems a logical recommendation for
transplant recipients, mainly for patients with a fair
skin type. Unfortunately, it is possible that the decades
of cumulative sun exposure before transplantation are
more important than the few years of exposure after it.
Finally, in patients with recurrent skin malignancies,
conversion to mTOR inhibitors may have a protective
effect against the development of new skin cancers.16
Smoking-Related Neoplasia
As smoking is a very signiﬁcant risk factor for the de-
velopment of neoplasia, smoking cessation should be
recommended to avoid the development of de novo ma-
lignancies. Once again, it is possible that cumulative
lifelong smoking is more important than active smok-
ing. In fact, active smokers did not have a higher risk of
malignancy than exsmokers.22 The relevance of avoid-
ing risk factors must be stressed in patients trans-
planted for alcoholic liver disease, not only because of
the association between alcohol and smoking but also
because alcohol consumption is a risk factor for neo-
plasia in the general population.23
As de novo neoplasia is one of the most frequent
causes of long-term mortality in liver transplant recip-
ients, some authors have suggested different surveil-
lance protocols. In our experience, the use of a strict
protocol has allowed us to diagnose neoplasia in some
patients at an early and potentially curative stage.10
This protocol has evolved over the years and includes
yearly urinanalysis, abdominal ultrasound, chest X-ray
ﬁlm, prostate speciﬁc antigen determination (for elderly
males), and ear-nose-throat examination and low-radi-
ation chest computed tomography scan (for smokers); it
also includes mammography every 2 years and colonos-
copy every 7 to 10 years (or more frequently in the case
of previous colonic adenomas and every year for pa-
tients with long-term ulcerative colitis).
CONCLUSIONS
De novo neoplasia is a frequent complication in liver
transplant recipients. It is one of the most frequent
causes of death in the long term. The main risk factors
for its development are EBV seronegativity (for lym-
phoma), ulcerative colitis (for colorectal cancer), sun
radiation (for skin cancer), smoking (for lung, head and
neck, and urological cancer), and increasing age. The
role of each immunosuppressive protocol in the risk of
cancer remains controversial. Unfortunately, preven-
tive measures and programs for the early diagnosis of
neoplasia cannot be widely recommended until the ev-
idence of their usefulness become stronger.
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